Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The report covers the month of March 2026, specifically detailing a share repurchase executed on March 17, 2026. The transaction was conducted through BNP Paribas SA as part of a non-discretionary agreement announced on February 17, 2026.
Key Financial Metrics and Transaction Details
The filing details a specific share buyback transaction rather than providing comprehensive financial statements (revenue, profit, cash flow).
- Shares Purchased: 732,112 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 2,002.00 GBp; highest price paid was 2,036.00 GBp.
- Volume-Weighted Average Price (VWAP): 2,016.45 GBp.
- Trading Venues: Purchases were executed across BATE, CHIX, and XLON (London Stock Exchange).
- Treasury Shares: Following this purchase, GSK holds 251,176,615 ordinary shares in treasury.
- Shares in Issue: 4,064,994,150 ordinary shares (excluding treasury shares).
- Voting Rights: Treasury shares represent 6.18% of total voting rights.
Material Changes and Program Progress
Since the commencement of the current buyback agreement on February 17, 2026, the Company has purchased a total of 11,285,521 ordinary shares. The March 17 transaction represents a continuation of this existing program. The filing confirms that the purchased shares are held as Treasury shares and do not carry voting rights.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, operational outlook, or management commentary regarding business performance. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties, referencing the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2025.
Key Facts for Investor Verification
- Verify the total remaining authorization under the buyback program announced on February 17, 2026, to assess the scale of future repurchases.
- Confirm the impact of the 6.18% treasury share holding on earnings per share (EPS) calculations and voting thresholds.
- Review the Annual Report on Form 20-F for 2025 for the specific risk factors referenced in the cautionary statement.
- Note that the filing does not disclose total cash outflow for the day, though it can be estimated using the VWAP and share count.